TrialCancer2020

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Sara E Kochanny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.